High-Sensitivity Cardiac Troponin I Is a Strong Predictor of Cardiovascular Events and Mortality in the AGES-Reykjavik Community-Based Cohort of Older Individuals.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Harris, Tamara B
Launer, Lenore J
MetadataShow full item record
CitationHigh-Sensitivity Cardiac Troponin I Is a Strong Predictor of Cardiovascular Events and Mortality in the AGES-Reykjavik Community-Based Cohort of Older Individuals. 2016, 62 (4):623-30 Clin. Chem.
AbstractThe objective of this study was to investigate the predictive power of a high-sensitivity cardiac troponin I (hs-cTnI) assay for cardiovascular events and mortality in a large population of older community dwellers.
Blood was collected from 5764 individuals (age 66-98 years) during the period of 2002-2006 and the outcome as to all-cause death and incidence of cardiovascular disease (CVD) and coronary heart disease (CHD) followed up to 10 years. hs-cTnI (Abbott) was measured in serum to assess the association of this marker with CVD, CHD and death, and finally, to compare the results with conventional risk factors by multivariable statistical analysis.
The median (interquartile range) concentrations of hs-cTnI were 8.4 ng/L (5.6-14.2 ng/L) and 5.3 ng/L (3.8-8.1 ng/L) in men (2416) and women (3275), respectively, and the concentrations increased linearly with age. Outcomes as to all-cause death and incidence of CVD and CHD were significantly associated with increasing concentrations of hs-cTnI beginning well below the 99th percentile concentrations. The associations with outcome remained after adjustments for conventional risk factors and were similar in men and women.
Our findings suggest that hs-cTnI reflects the status of the myocardium even in seemingly healthy individuals and that the measurements of hs-cTnI may be useful for primary prediction of heart disease; this should form the basis for future prospective clinical trials for determining whether measuring hs-cTnI can be used in the prevention of CVD/CHD.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Clinical chemistry
- High-sensitivity cardiac troponin I and risk of cardiovascular disease in an Australianpopulation-based cohort.
- Authors: Zhu K, Knuiman M, Divitini M, Murray K, Lim EM, St John A, Walsh JP, Hung J
- Issue date: 2018 Jun
- High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.
- Authors: Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM
- Issue date: 2019 Jun 4
- Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study.
- Authors: Omland T, de Lemos JA, Holmen OL, Dalen H, Benth JŠ, Nygård S, Hveem K, Røsjø H
- Issue date: 2015 Apr
- Factors influencing the 99th percentile of cardiac troponin I evaluated in community-dwelling individuals at 70 and 75 years of age.
- Authors: Eggers KM, Lind L, Venge P, Lindahl B
- Issue date: 2013 Jul
- Association of Repeatedly Measured High-Sensitivity-Assayed Troponin I with Cardiovascular Disease Events in a General Population from the MORGAM/BiomarCaRE Study.
- Authors: Hughes MF, Ojeda F, Saarela O, Jørgensen T, Zeller T, Palosaari T, O'Doherty MG, Borglykke A, Kuulasmaa K, Blankenberg S, Kee F
- Issue date: 2017 Jan